← All Compounds
Mechanism Nonapeptide that modulates sleep architecture. Acts on multiple targets including GABA-A receptors, serotonergic pathways, and cortisol regulation. Promotes delta-wave sleep onset without causing sedation. Half-Life Approximately 15-25 minutes Route subcutaneous Frequency Once daily (before sleep)
FDA Category Research peptide (FDA Category 2) Reclassification pending Date Restricted 2023-09-29 Announced Return 2026-02-27
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
DSIP (Delta Sleep-Inducing Peptide / Emideltide)
Cat 2 → Pending Cat 1Neuropeptide · Research peptide (multiple suppliers)
Nonapeptide researched for sleep architecture modulation and stress-related cortisol regulation. Not FDA-approved for any indication.
About
Clinical Dosing
100-300 mcgonce daily (before sleep)
Not FDA-approved. Limited human clinical data. Currently FDA Category 2 (restricted). Pending return to Category 1.
Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Research Protocol
Source: Kovalzon & Strekalova, Peptides, 2006
| Dose | Duration | Draw (2 mg vial in 2mL) | Notes |
|---|---|---|---|
| 100 mcg | Maintenance | 0.10 mL (10 units) | Standard research dose before sleep |
Available Vial Sizes
2 mg
2 mg vial
5 mg
5 mg vial
Citations
- [1]Delta Sleep-Inducing Peptide: An Update. Peptides, 27(6), 1455-1461. Link(Reviewed: 2026-02-27)